|drug218||Angiotensin 1-7 Wiki||0.50|
|D045169||Severe Acute Respiratory Syndrome NIH||0.03|
|D018352||Coronavirus Infections NIH||0.02|
There are 2 clinical trials
Hydroxychloroquine has been approved by FDA as one of the treatment options for COVID 19.Healthcare personnel are amongst those at highest risk to contract the disease. Several health authorities are now recommending the use of hydroxychloroquine as pre-exposure prophylaxis is in health care personnel. Several studies are on going in this context. However there is a controversy regarding the dosage regimen. This drug has a half life of 22.4 days. In this study we will be comparing three different doses of Hydroxychloroquine and additionally have a control group in order to determine the efficacy of hydroxychloroquine as pre- exposure prophylaxis in healthcare personnel in various doses.
Description: Outcome reported as the percentage of participants in each arm who are COVID-19-free at the end of study treatmentMeasure: COVID-19-free survival in experimental arms compared to placebo Time: 12 weeks
Description: Outcome reported as the percent of participants in each arm who have a confirmed SARS-CoV-2 infection during study treatment.Measure: Incidence of confirmed SARS-COV-2 detection Time: 12 weeks
Description: Outcome reported as the percent of participants in each arm who report COVID-19-related symptoms during study treatmentMeasure: Incidence of possible COVID-19 symptoms Time: 12 weeks
Description: Outcome reported as the percent of participants in each arm who discontinue study medication use for any reason during treatment.Measure: Incidence of all-cause study medicine discontinuation Time: 12 weeks
Description: Participants will self-report COVID-19 status on an ordinal scale as follows: No illness (score=1), Illness with outpatient observation (score=2), Hospitalization (or post-hospital discharge) (score=3), Hospitalization with ICU stay (score 4),Death from COVID 19(score=5) Possible scores range from 1-5 with higher scores indicating greater disease severity.Measure: Ordinal Scale of COVID-19 Disease maximum severity if COVID-19 diagnosed at study end Time: 12 weeks
Description: Outcome reported as the percent of participants in each arm who are hospitalized or expire due to COVID-19 during study treatment.Measure: Incidence of Hospitalization for COVID-19 or death Time: 12 weeks
Description: Outcome reported as the percent of participants experiencing any possible adverse events from HydroxychloroquineMeasure: Incidence of study medication-related adverse events Time: 12 weeks
The PROTECT open-label randomised basket trial will assess the effectiveness of hydroxychloroquine (HCQ) as chemoprophylaxis against COVID-19 in multiple vulnerable populations in the United Kingdom.
Description: The primary outcome for PROTECT is the time to confirmed COVID-19 infection from the date of randomisation. This will be captured via linkage with PHE or by direct reporting by sites.Measure: Time to confirmed diagnosis of COVID-19 Time: To study completion, average 6 months
Description: Death from any causeMeasure: All-cause mortality Time: To study completion, average 6 months
Description: Severity will be assessed by requirement for hospitalisation, HDU/ICU admission or death and Length of inpatient stay.Measure: Severity of COVID-19 disease Time: To study completion, average 6 months
Description: Acute respiratory distress syndrome, viral pneumonitis, myocarditis/myocardial injury, acute kidney injury.Measure: Incidence of COVID-19 complications Time: To study completion, average 6 months
Data processed on December 13, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports